HDAC Inhibition as a Treatment Concept to Combat Temsirolimus-Resistant Bladder Cancer Cells

Oncotarget - United States
doi 10.18632/oncotarget.22454
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors
Publisher

Impact Journals, LLC

Related search

Inhibition of mTOR by Temsirolimus Contributes to Prolonged Survival of Mice With Pleural Dissemination of Non-Small-Cell Lung Cancer Cells

Cancer Science
Cancer ResearchMedicineOncology
2011English

Differential Response of Cancer Cells to HDAC Inhibitors Trichostatin a and Depsipeptide

British Journal of Cancer
Cancer ResearchOncology
2011English

Targeting Dendritic Cells as a Good Alternative to Combat Leishmania Spp.

Frontiers in Immunology
AllergyImmunology
2014English

Knockdown of MTDH Increases Drug Sensitivity to HDAC Inhibitor and TRAIL Combination Treatment in Endometrial Cancer Cells

Proceedings in Obstetrics and Gynecology
2011English

New and Emerging HDAC Inhibitors for Cancer Treatment

Journal of Clinical Investigation
Medicine
2014English

Oral Melphalan as a Treatment for Platinum-Resistant Ovarian Cancer

British Journal of Cancer
Cancer ResearchOncology
2003English

TYRO3 as a Molecular Target for Growth Inhibition and Apoptosis Induction in Bladder Cancer

British Journal of Cancer
Cancer ResearchOncology
2019English

EGFR Family Inhibition Identifies P38 MAPK as a Potential Therapeutic Target in Bladder Cancer

Urology
Urology
2018English

PPARγ Inhibition Regulates the Cell Cycle, Proliferation and Motility of Bladder Cancer Cells

Journal of Cellular and Molecular Medicine
Molecular MedicineCell Biology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy